In 2015, Corrales et al. reported that CDNs can bind to the ligand-binding domain of STING and activate it, thereby affecting the vascular system and tumor microenvironment and initiating the activities of APC (antigen-presenting cells) and CD8+ T cells (Corrales et al., 2015). The gene discussed is STING1; the disease is neoplasm.